Vaxcyte (PCVX) catalysts

Upcoming FDA decisions and readouts we track for Vaxcyte, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 07 Oct 2026

FreeBioList tracks 1 upcoming catalyst for Vaxcyte (PCVX, listed on Nasdaq). It concerns VAX-31 (Pneumococcal disease prevention in adults).

First on the list: the Phase 3 readout for VAX-31 (Pneumococcal disease prevention in adults), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker: PCVX
Next catalyst: H1 2027
Type: Phase 3 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Vaxcyte PCVX · Nasdaq	VAX-31	Pneumococcal disease prevention in adults	H1 2027 company guidance	Phase 3 readout	Verified	8-K exhibit 99.2 ↗	Yes
Notes — Presentation states OPUS-2 (with seasonal flu vaccine) and OPUS-3 (previously vaccinated adults) have completed enrolment, with "topline results anticipated 1H 2027". The OPUS-1 pivotal topline was reported 5 Oct 2026 and met all primary immunogenicity endpoints. Source: 8-K exhibit 99.2, filed 05 Oct 2026 · verified 07 Oct 2026